Time-to-treatment window and cross-sex potential of β
Adrenergic beta-2 Receptor Agonists
/ administration & dosage
Animals
Body Composition
/ drug effects
Disease Models, Animal
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Formoterol Fumarate
/ administration & dosage
Male
Mice, Inbred C57BL
Mitochondria, Muscle
/ drug effects
Muscle, Skeletal
/ drug effects
Organelle Biogenesis
Receptors, Adrenergic, beta-2
/ drug effects
Recovery of Function
Sex Factors
Spinal Cord
/ drug effects
Spinal Cord Injuries
/ drug therapy
Time Factors
Time-to-Treatment
Formoterol
Locomotor recovery
Mitochondrial biogenesis
Spinal cord injury
Journal
Toxicology and applied pharmacology
ISSN: 1096-0333
Titre abrégé: Toxicol Appl Pharmacol
Pays: United States
ID NLM: 0416575
Informations de publication
Date de publication:
15 01 2021
15 01 2021
Historique:
received:
02
11
2020
revised:
03
12
2020
accepted:
07
12
2020
pubmed:
15
12
2020
medline:
12
5
2021
entrez:
14
12
2020
Statut:
ppublish
Résumé
Mitochondrial dysfunction is a well-characterized consequence of spinal cord injury (SCI). We previously reported that treatment with the FDA-approved β
Identifiants
pubmed: 33316273
pii: S0041-008X(20)30488-9
doi: 10.1016/j.taap.2020.115366
pii:
doi:
Substances chimiques
ADRB2 protein, mouse
0
Adrenergic beta-2 Receptor Agonists
0
Receptors, Adrenergic, beta-2
0
Formoterol Fumarate
W34SHF8J2K
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
115366Subventions
Organisme : BLRD VA
ID : IK2 BX005218
Pays : United States
Informations de copyright
Published by Elsevier Inc.